本文關(guān)鍵詞：荔枝核總黃酮及羅格列酮對大鼠肝星狀細胞PPAR-γ和CTGF表達的影響　出處：《桂林醫(yī)學院》2016年碩士論文　論文類型：學位論文

  更多相關(guān)文章： 荔枝核總黃酮 羅格列酮 大鼠肝星狀細胞 過氧化物酶體增殖物激活受體γ 結(jié)締組織生長因子

【摘要】：目的:研究中藥荔枝核總黃酮(total flavonoids of litchi,TFL)對大鼠肝星狀細胞(HSC-T6)增殖的影響并與西藥羅格列酮作對照,初步探討TFL抗肝纖維化的相關(guān)作用機制。方法:采用篩選出的不同濃度(40、80、160μg/mL)的TFL及15μmol/L的羅格列酮作用于HSC-T6,MTT法檢測TFL及羅格列酮對HSC-T6增殖的影響;Quantitative Real-time PCR法檢測TFL和羅格列酮對HSC-T6過氧化物酶體增殖物激活受體γ(peroxisome proliferator-activated receptor-γ,PPAR-γ)和結(jié)締組織生長因子(connective tissue growth factor,CTGF)mRNA表達的影響;Westen blot法檢測TFL和羅格列酮對HSC-T6 CTGF蛋白表達的影響。結(jié)果:TFL作用48、72 h可以明顯抑制HSC-T6增殖,且在一定范圍(40-160μg/mL)內(nèi)隨時間延長及藥物濃度增加,抑制作用更加明顯。加藥72 h后,高、中、低濃度的TFL及羅格列酮對HSC-T6的抑制率分別為12.53%±0.30%,22.82%±1.24%,30.73%±0.23%,22.47%±0.42%,TFL組A值與正常組比較差異有統(tǒng)計學意義(P0.05),高、低濃度TFL組A值與羅格列酮組比較差異有統(tǒng)計學意義(P0.05),中濃度TFL組A值與羅格列酮組比較差異無統(tǒng)計學意義(P0.05)。TFL和羅格列酮處理72小時后均能上調(diào)HSC-T6 PPAR-γmRNA的表達,下調(diào)CTGF mRNA及蛋白的表達(p0.05);與羅格列酮組相比,TFL組上調(diào)PPAR-γmRNA表達的能力均明顯降低(p0.05),低濃度TFL組CTGF mRNA及蛋白表達水平增高(p0.05),中濃度TFL組與羅格列酮組CTGF mRNA及蛋白表達量差異無統(tǒng)計學意義(p0.05),高濃度TFL組CTGF mRNA及蛋白表達水平減低(p0.05);隨濃度增加,TFL組PPAR-γmRNA的表達水平依次增高(p0.05),CTGF mRNA及蛋白的表達水平依次減低(p0.05)。結(jié)論:TFL和羅格列酮均能夠抑制HSC-T6增殖從而拮抗肝纖維化,且在一定范圍內(nèi)有劑量時間依賴性,此種抑制作用可能是通過增強PPAR-γ的活性,從而抑制下游細胞因子CTGF的表達來實現(xiàn)的。
[Abstract]:Objective: to study the total flavonoids of litchi. The effect of TFL on the proliferation of rat hepatic stellate cells (HSC-T6) was compared with rosiglitazone. Objective: to explore the mechanism of anti-hepatic fibrosis by TFL. Methods: different concentrations of TFL were used to study the mechanism of anti-hepatic fibrosis. 160 渭 g / mL TFL and 15 渭 mol/L rosiglitazone were used to detect the effect of TFL and rosiglitazone on HSC-T6 proliferation. Detection of HSC-T6 peroxisome proliferator activated receptor 緯 (緯) by TFL and rosiglitazone by Quantitative Real-time PCR. Peroxisome proliferator-activated receptor- 緯. PPAR- 緯) and connective tissue growth factor (CTGF- 緯) mRNA expression; The effect of TFL and rosiglitazone on the expression of HSC-T6 CTGF protein was detected by Westen blot. The proliferation of HSC-T6 was inhibited obviously at 72 h, and the inhibitory effect was more obvious with the prolongation of time and the increase of drug concentration within a certain range of 40 ~ 160 渭 g / mL. After 72 h of administration, the inhibitory effect was more obvious. The inhibitory rates of high, medium and low concentrations of TFL and rosiglitazone on HSC-T6 were 12.53% 鹵0.30% 鹵1.2472% 鹵1.240.73% 鹵0.23%, respectively. The value of A in 22.47% 鹵0.42% TFL group was significantly higher than that in the normal group (P 0.05). Compared with rosiglitazone group, the A value of low concentration TFL group was significantly different from that of rosiglitazone group (P 0.05). There was no significant difference in A value between TFL group and rosiglitazone group (P 0.05). Both TFL and rosiglitazone could up-regulate the expression of HSC-T6 PPAR- 緯 mRNA after 72 hours treatment. The expression of CTGF mRNA and protein was down-regulated (P 0.05). Compared with rosiglitazone group, the ability of upregulation of PPAR- 緯 mRNA in TFL group was significantly lower than that in rosiglitazone group (P 0.05). The expression of CTGF mRNA and protein in low concentration TFL group was higher than that in control group (p0.05). There was no significant difference in the expression of CTGF mRNA and protein between TFL group and rosiglitazone group (p 0.05). The expression of CTGF mRNA and protein in high concentration TFL group decreased p0.05; The expression level of PPAR- 緯 mRNA in TFL group increased in turn with the increase of concentration (p0.05). The expression level of CTGF mRNA and protein decreased in turn (P 0.05). Conclusion both CTGF and rosiglitazone can inhibit the proliferation of HSC-T6 and antagonize liver fibrosis. The inhibition may be achieved by increasing the activity of PPAR- 緯 and thus inhibiting the expression of downstream cytokine CTGF.
【學位授予單位】：桂林醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前10條

1 Hussein M Atta;;Reversibility and heritability of liver fibrosis:Implications for research and therapy[J];World Journal of Gastroenterology;2015年17期

2 徐伶俐;羅偉生;譚寧;徐慶;徐賓;諸葛福艷;;p27在荔枝核總黃酮抑制人肝星狀細胞LX2增殖過程中的表達及其意義[J];世界華人消化雜志;2015年04期

3 Wen-Ce Zhou;Quan-Bao Zhang;Liang Qiao;;Pathogenesis of liver cirrhosis[J];World Journal of Gastroenterology;2014年23期

4 吳紅媛;厲建中;張俊平;;中藥對組織器官纖維化防治機制研究[J];中國實驗方劑學雜志;2013年21期

5 喻勤;傅向陽;羅偉生;;以肝星狀細胞為靶點的抗肝纖維化治療進展[J];醫(yī)藥導報;2013年03期

6 靳雅玲;羅偉生;歐士鈺;覃浩;孫旭銳;;荔枝核總黃酮對肝纖維化大鼠肝細胞凋亡機制的研究[J];時珍國醫(yī)國藥;2012年09期

7 石玉香;袁靜萍;官陽;楊木蘭;徐惠;羅波;;羅格列酮對肝星狀細胞的生物學特性及PDGF表達的影響[J];臨床與實驗病理學雜志;2011年10期

8 李偉;楊兆麗;詹利之;林燕芳;張美義;宋健平;;荔枝核總黃酮提取測定方法及工藝的優(yōu)化[J];中醫(yī)學報;2011年06期

9 ;Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats[J];Hepatobiliary & Pancreatic Diseases International;2011年01期

10 薛苗;毛小榮;陳紅;;CTGF——肝纖維化治療新亮點[J];國際消化病雜志;2010年04期

，

本文編號：1423832